← Back to Search

Neurotoxin

Botox Injections for Overactive Bladder

N/A
Waitlist Available
Led By Lisa Peacock, MD
Research Sponsored by Louisiana State University Health Sciences Center in New Orleans
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Pursuing treatment with intravesical botulinum toxin injections
Be older than 18 years old
Must not have
Non-OAB diagnosis such as pelvic pain or interstitial cystitis
Timeline
Screening 3 weeks
Treatment Varies
Follow Up days from initial injection to repeat injection, up to 365 days
Awards & highlights

Summary

"This trial aims to determine if allowing patients to decide their own follow-up times after receiving Botox injections for overactive bladder can improve treatment effectiveness. They want to find out if the time between injections

Who is the study for?
This trial is for individuals with overactive bladder and related urinary issues who have previously responded to botulinum toxin injections. Participants will decide when they need follow-up treatments rather than following a standard schedule.
What is being tested?
The study tests if patient-directed follow-up times for botulinum toxin injections into the bladder are more effective than the usual 6-month interval in managing symptoms of overactive bladder.
What are the potential side effects?
Botulinum toxin may cause side effects like urinary tract infections, difficulty urinating, or discomfort at the injection site. Some people might also experience general weakness.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am considering or planning to receive Botox injections in my bladder.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have been diagnosed with conditions like pelvic pain or interstitial cystitis, not OAB.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~days from initial injection to repeat injection, up to 365 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and days from initial injection to repeat injection, up to 365 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Injection interval
Secondary study objectives
Patient Satisfaction
Symptom Control

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Patient-directed follow upExperimental Treatment1 Intervention
Post-operative follow up interval for repeat injection decided by patient based on OAB symptomatology (3-12 months)
Group II: Standard of careActive Control1 Intervention
Standard 6 month post-operative follow up interval for repeat injection

Find a Location

Who is running the clinical trial?

Louisiana State University Health Sciences Center in New OrleansLead Sponsor
119 Previous Clinical Trials
44,728 Total Patients Enrolled
Lisa Peacock, MDPrincipal InvestigatorLouisiana State University Health Science Center - New Orleans
~67 spots leftby Jul 2025